Iterum Therapeutics to Announce Q2 2025 Earnings on Aug 5, 2025

Iterum Therapeutics plans to release Q2 2025 financial results on August 5, 2025, before the US market opens. A conference call will be held at 8:30 a.m. ET to discuss the financial outcomes and business developments. Investors can join via phone or webcast using access code 740801. Iterum Therapeutics is focused on addressing multi-drug resistant pathogens through its innovative anti-infective solutions, including the approved New Drug Application for ORLYNVAH (oral sulopenem).

Iterum Therapeutics plc (Nasdaq: ITRM), a biopharmaceutical company focused on delivering next-generation oral and IV antibiotics to treat multi-drug resistant pathogens, will release its second quarter 2025 financial results on August 5, 2025, before the U.S. market opens. The company will host a conference call at 8:30 a.m. ET to discuss the financial outcomes and provide an update on its business developments [1][2][3].

Investors and financial professionals can join the call by dialing 833-470-1428 (domestic) or 404-975-4839 (international) and using the access code 740801. Alternatively, the audio webcast can be accessed under "Financials & Filings" in the Investors section of the company's website at www.iterumtx.com following the call [1][2][3].

Iterum Therapeutics is committed to addressing the global crisis of multi-drug resistant pathogens through its innovative anti-infective solutions. The company has received approval of its New Drug Application (NDA) for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by specific microorganisms in adult women with limited or no alternative oral antibacterial treatment options. Additionally, it has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications [1][2][3].

The upcoming financial results will provide insights into the company's financial health, market performance, and progress in its pipeline of anti-infective solutions. Investors and analysts will be keen to understand the company's revenue growth, expenses, and any updates on its clinical trials and regulatory approvals.

References:
[1] https://www.globenewswire.com/news-release/2025/07/29/3123163/0/en/Iterum-Therapeutics-to-Report-Second-Quarter-2025-Financial-Results-on-August-5-2025.html
[2] https://finance.yahoo.com/news/iterum-therapeutics-report-second-quarter-120000509.html
[3] https://www.morningstar.com/news/globe-newswire/9501592/iterum-therapeutics-to-report-second-quarter-2025-financial-results-on-august-5-2025